



# Impact of DNA methylation of the human mesoderm-specific transcript (*MEST*) on male infertility

Tayebeh Amjadian<sup>a</sup>, Parichehreh Yaghmaei<sup>a</sup>, Hayati Roodbari Nasim<sup>a</sup>,  
Kheirollah Yari<sup>b,\*</sup>

<sup>a</sup> Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

<sup>b</sup> Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

## ARTICLE INFO

### Keywords:

Infertility  
Sperm  
Methylation  
*MEST* gene  
Differentially methylated region (DMR)

## ABSTRACT

Male infertility accounts for nearly 40%–50% of all infertile cases. One of the most prevalent disorders detected in infertile men is errors in the *MEST* differentially methylated region (DMR), which has been correlated with poor sperm indexes. The aim of our study was to characterize the methylation pattern of the *MEST* gene, along with assessing seminal factors and chromatin condensation in sperm samples from both infertile patients and fertile cases, all of whom were candidates for intracytoplasmic sperm injection. We collected forty-five semen specimens from men undergoing routine spermogram analysis at the Infertility Treatment Center. The specimens consisted of 15 samples of normospermia as the control group, 15 individuals of asthenospermia, and 15 individuals of oligoasthenoteratospermia as the cases group. Standard semen analysis and the chromatin quality and sperm maturity tests using aniline blue staining were performed. The DNA from spermatozoa was extracted and treated with a sodium bisulfite-based procedure. The methylation measure was done quantitatively at the DMRs of the *MEST* gene by quantitative methylation-specific polymerase chain reaction (qMSP). The mean percentages of total motility, progression, and morphology in normospermia were significantly higher than oligoasthenoteratospermia and asthenospermia, and they were substantially higher in asthenospermia compared to oligoasthenoteratospermia ( $P \leq 0.05$ ). The mean percentages of histone transition abnormality and *MEST* methylation in oligoasthenoteratospermia were significantly higher than asthenospermia and normospermia ( $P \leq 0.05$ ). A negative correlation existed between the histone transition abnormality and *MEST* methylation with sperm parameters. In conclusion, chromatin integrity, sperm maturity, and *MEST* methylation may be considered important predictors for addressing male factor infertility. Therefore, we suggest that male infertility may be linked to methylation of the imprinted genes.

## 1. Introduction

Sexual disorders in men cover a wide range of issues, varying from Erectile Dysfunction (ED) to infertility, indicating the diverse and complex nature of male-related problems in this domain in various nations [1–3]. Infertility is a serious health problem globally

\* Corresponding author. Medical Biology Research Center, Medical school, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

E-mail addresses: [khirollah.yari@yahoo.com](mailto:khirollah.yari@yahoo.com), [kyari@kums.ac.ir](mailto:kyari@kums.ac.ir) (K. Yari).

<https://doi.org/10.1016/j.heliyon.2023.e21099>

Received 8 April 2023; Received in revised form 11 September 2023; Accepted 16 October 2023

Available online 16 October 2023

2405-8440/© 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

affecting 15 % of reproductive-aged couples [4,5]. It is worth noting that male infertility is accounted for approximately 40%–50 % of infertile persons [6]. The heritable and acquired disturbances of the hypothalamic-pituitary-testicular endocrine, anatomical disorders, chromosomal abnormalities, and mutations are well-introduced as potential causes of male infertility. Nevertheless, the etiology remains unclear for most infertile men [7]. Assisted reproductive technology (ART) has significantly developed new procedures and therapies for male infertility. Since the first child was born via in vitro fertilization, ART has contributed to more than 5 million birth and continued to progress quickly [8]. However, ART and infertility may be related to epigenetic disorders [9]. Epigenetics is assigned to mitosis or meiotic heredity variations in genes that cannot be illustrated by alterations in the sequence of DNA, comprising a wide range of modifications such as histone transition abnormality, DNA methylation, and noncoding RNAs. Any disturbances of epigenetic adjustment caused by the ART approach or abnormal spermatogenesis disrupt sperm function and transfer to future generations and lead to epigenetic diseases [10].

Cancer epigenetics play a crucial role in the continuous quest for discovering biomarkers in different types of cancer [11,12]. In germ cell epigenetics, recent progression also has facilitated the detection of male factor infertility predictive markers. Differential cytosine methylation in CpG islands, especially by imprinted genes e.g., *MEST* gene influences gene regulation [13].

The congenital imprints are eliminated in the fetus and created again based on embryo sexuality in gametogenesis. Uncorrected imprinting leads to aberrant fetal growth and virulent diseases [14]. In addition, imprinting disorders have been found in classical genetic disturbances for instance Silver–Russell. The prevalence of classical genetic diseases is elevated in those who received ART [15]. Furthermore, prior documents have reported aberrant methylation within imprinting and non-imprinting genes related to various sorts of infertility in men [16,17].

By next-generation bisulfite sequencing, another study demonstrated that differentially methylated regions (DMRs) of imprinted genes, including *SNRPN*, *MEG8*, *GNAS*, and *H19* revealed distinct methylation patterns in the abnormal semen groups [18].

The PEG1 gene, paternally expressed gene 1, known as the human mesoderm-specific transcript (*MEST*) gene, is an imprinted gene placed on chromosome 7q32.2 [19]. An enzyme of the  $\alpha/\beta$ -hydrolase fold family is encoded by the *MEST* gene. *MEST* comprises two basic isoforms, which show mono-allelic and bi-allelic expressions. The *MEST* gene promoter of the active paternal alleles is completely hypomethylated in normal status [20]. Although the *MEST* gene promoter of the silent maternal alleles is transcriptionally hypermethylated and it regulates the monoallelic expression of the *MEST* gene, the imprinted *MEST* gene is also a candidate gene for Silver-Russell syndrome [21].

Unregulated expression of the *MEST* gene has been related to breast cancer, colorectal cancer, uterine leiomyoma, and lung cancer cell lines in humans [22,23], and growth retardation and elevated mortality in mice [24].

According to documents, ART procedures affect *MEST* gene methylation [25]. Likewise, aberrant expression of the *MEST* gene is responsible for some forms of male infertility. In previous studies, oligozoospermic men and those with idiopathic infertility have reported hypermethylation at the *MEST* differentially methylated region (DMR) [26,27]. *MEST* DMR methylation errors were the prevalent disorders detected in infertile men compared to other imprinted genes [28]. Moreover, a previous study illustrated that *MEST* DMR methylation is correlated with poor sperm indexes [29].

On the other hand, sperm chromatin condensation is another crucial factor that can serve as an index of sperm quality. Consequently, it may have a negative impact on both natural fertility outcomes and ART results, such as pregnancy failure and decreased birth rate [30,31]. In spermatogenesis, DNA histones are predominantly substituted with protamines, leading to a tightly condensed sperm chromatin structure. An alternative indirect method involves using aniline blue staining to identify any surplus histones, thereby indirectly suggesting lower levels of protamines within the sperm nucleus. To put it simply, aniline blue staining detects the lingering histones by binding to the lysine-rich histones present. This technique helps in assessing the chromatin remodeling process during sperm development [32,33].

This study aimed to characterize the methylation status of the *MEST* gene, seminal parameters, and chromatin integrity in sperm samples from infertile patients and fertile cases who were candidates for intracytoplasmic sperm injection (ICSI). For the first time, the current study evaluated the *MEST* methylation in infertile groups, especially oligoasthenoteratospermia.

## 2. Materials and methods


### 2.1. Sample collection

This research as a case-control study was carried out on infertile cases who were candidates for intra cytoplasmic sperm injection (ICSI) in the Infertility Treatment and Andrology Institute located in Kermanshah-Iran. Participants with a history of previous varicocele surgery, smoking, alcohol consumption, and drug abuse were excluded from the study. Eventually, fifteen men with asthenospermia and fifteen men with oligoasthenoteratospermia were included in the analysis as the case groups. The normozoospermic group (n = 15) was considered the control group. All participants were required to sign a written consent form and were provided with a participant information statement that thoroughly explained the consent process. The Research Ethics Committee at the Deputy of Research of Islamic Azad University approved the study protocol (IR.IAU.SRB.REC.1401.184). Additionally, patients who either refused to participate or did not meet the necessary criteria based on sperm characteristics were excluded from the study. The sampling process lasted from August to November 2021.

### 2.2. Sperm parameters analysis

All samples were collected following the standard method and an abstinence protocol, with intervals ranging from 2 to 7 days [34].





**Fig. 1.** PCR products from a bisulfite-modified DNA using the methylated and unmethylated primer pairs were electrophoresed on a 2% agarose gel.

abnormality in oligoasthenoteratospermia were significantly higher than asthenospermia and normospermia ( $P < 0.05$ ) (Table 2).

Respectively, normal sperm were known as unstained or pale blue and dark blue cells, and aberrant spermatozoa were recognized as dark blue stained cells. Table 3 illustrates a negative relationship between abnormal spermatozoa chromatin condensation with spermatozoa count ( $r = -0.373$ ;  $P = 0.012$ ), concentration ( $r = -0.350$ ;  $P = 0.019$ ), total motility ( $r = -0.406$ ;  $P = 0.006$ ), progressive ( $r = -0.405$ ;  $P = 0.006$ ), and normal morphology ( $r = -0.426$ ;  $P = 0.004$ ).

Table 4 demonstrates that the mean percentages of *MEST* methylation were higher in infertile compared to normospermia ( $P < 0.05$ ). The mean percentages of *MEST* methylation in oligoasthenoteratospermia were significantly higher than in asthenospermia and normospermia ( $P < 0.05$ ).

Table 5 illustrates a negative correlation between *MEST* methylation with spermatozoa count ( $r = -0.374$ ;  $P = 0.011$ ), concentration ( $r = -0.325$ ;  $P = 0.029$ ), progressive ( $r = -0.323$ ;  $P = 0.030$ ), and normal morphology ( $r = -0.384$ ;  $P = 0.009$ ).

#### 4. Discussion

In our study, the seminal assessment was carried out for normozoospermia, which is categorized as the case group, and asthenospermia and oligoasthenoteratospermia were considered as case group(s). For the first time, this research evaluated the status of the *MEST* gene and sperm maturity simultaneously in abnormal samples, especially in oligoasthenoteratospermia groups, and normal sperm samples. Furthermore, the research considered assessing the role of chromatin maturity in categorizing the sperm as typical and atypical as another aim.

To opt for choosing the best evaluation, there were three factors related to sperm that were considered in this study: sperm parameters, chromatin quality, and status of *MEST* methylation in fertile and infertile groups.

According to sperm parameters, results demonstrated a statistically considerable difference in spermatozoa parameters between the normozoospermic (control) and the infertile group, as the case group, and among oligoasthenoteratospermia, asthenospermia, and normozoospermia (Table 2). These findings are in accordance with a retrospective study done by Pourmasumi et al. indicating a remarkable difference in sperm parameters between normozoospermia and infertile groups [41]. Moreover, a study on Erbil population showed a considerable negative association between infertility and sperm characteristics, e.g., viability, volume, concentration, total count, total motility, progressive motility, and morphology [42].

In spermiogenesis, histones are replaced by protamines in the chromatin of the nucleus, which is crucial for chromatin condensation and stability. Therefore, mature spermatozoa (normal) were characterized by pale blue and dark blue sperm heads, while immature sperm (abnormal) were identified by dark blue or gray coloration.

The findings of our study illustrated a significantly negative relationship between histone transition abnormality via  $AB^+$  cells with spermatozoa count, concentration, total motility, progressive, and normal morphology (Table 3). Pourmasumi and colleagues reported similar findings with 1386 overall sample size [41]. Moreover, Al-Fahhamet et al. observed a considerable negative association between chromatin results of AB and toluidine blue (TB) staining with spermatozoa concentration, morphology, and progressive motility too [43]. Additionally, in a study done by Kim and coworkers, a remarkable correlation between chromatin maturity with normal sperm stained by AB and TB staining was reported [44]. Sellami et al. demonstrated a negative relationship between sperm maturity and histone transition abnormality [45]. Furthermore, a study performed by Hammadeh and coworkers reported a meaningful difference

**Table 2**  
Sperm parameters in normospermia group and infertile subgroups.

| Sperm parameters                                  | Normozoospermic (n = 15) |               | Infertile (n = 30) |              | P <sup>a</sup> | Normozoospermic (n = 15) |               | Asthenospermia (n = 15) |               | Oligoasthenoteratospermia (n = 15) |             | P <sup>b</sup> |
|---|--------------------------|---------------|--------------------|--------------|----------------|--------------------------|---------------|-------------------------|---------------|------------------------------------|-------------|----------------|
|   | Mean ± SD                | 95 %CI        | Mean ± SD          | 95 %CI       |                | Mean ± SD                | 95 %CI        | Mean ± SD               | 95 %CI        | Mean ± SD                          | 95 %CI      |                |
| Sperm Count (10 <sup>6</sup> cells per ejaculate) | 144.18 ± 53.44           | 115.02–169.30 | 105.0 ± 97.56      | 72.61–139.51 | 0.030          | 144.18 ± 53.44           | 114.58–173.78 | 180.73 ± 84.52          | 133.92–227.54 | 29.26 ± 16.84                      | 19.93–38.59 | 0.001          |
| Sperm Concentration (10 <sup>6</sup> cells/mL)    | 56.85 ± 15.18            | 49.91–65.20   | 28.36 ± 22.92      | 20.10–36.37  | 0.001          | 56.85 ± 15.18            | 48.44–65.26   | 47.66 ± 16.35           | 38.60–56.72   | 9.06 ± 4.78                        | 6.41–11.71  | 0.001          |
| Total Motility (%)                                | 54.64 ± 8.86             | 50.21–59.88   | 27.50 ± 10.32      | 23.84–30.89  | 0.001          | 54.64 ± 8.86             | 49.73–59.54   | 33.40 ± 4.27            | 31.03–35.76   | 21.60 ± 11.31                      | 15.33–27.86 | 0.001          |
| Progressive (%)                                   | 32.53 ± 1.24             | 30.0–33.25    | 9.53 ± 6.18        | 7.23–11.48   | 0.001          | 32.53 ± 1.24             | 31.84–33.22   | 13.93 ± 4.72            | 11.31–16.55   | 5.13 ± 3.92                        | 2.95–7.30   | 0.001          |
| Morphology (%normal)                              | 4.73 ± 0.45              | 4.50–4.94     | 1.30 ± 0.87        | 1.0–1.61     | 0.001          | 4.73 ± 0.45              | 4.47–4.98     | 2.06 ± 0.25             | 1.92–2.20     | 0.53 ± 0.51                        | 0.24–0.81   | 0.001          |
| Histone transition abnormality (%)                | 0.07 ± 0.04              | 0.01–0.07     | 0.09 ± 0.05        | 0.07–0.11    | 0.068          | 0.07 ± 0.04              | 0.04–0.09     | 0.07 ± 0.03             | 0.04–0.09     | 0.12 ± 0.05                        | 0.08–0.15   | 0.002          |

<sup>a</sup> Relationships between sperm parameters in normospermia and infertile group were determined with the nonparametric Mann-Whitney *U* test.

<sup>b</sup> *P*-value obtained from the difference between means in normospermia, asthenospermia, and oligoasthenoteratospermia was tested for significance, by Kruskal-Wallis one way ANOVA on ranks and post hoc analysis was performed using Dunn's for all pair-wise comparisons. *p* < 0.05 was considered statistically significant.

**Table 3**  
Correlation between sperm parameters with abnormal sperm chromatin condensation.

| Sperm parameters                          | Total  |       | Normozoospermic |       | Asthenospermia |       | Oligoasthenoteratospermia |       |
|---|--------|-------|-----------------|-------|----------------|-------|---------------------------|-------|
|   | r      | P     | r               | P     | r              | P     | r                         | P     |
| Sperm Count ( $10^6$ cells per ejaculate) | -0.373 | 0.012 | 0.200           | 0.476 | -0.162         | 0.565 | 0.262                     | 0.345 |
| Sperm Concentration ( $10^6$ cells/mL)    | -0.350 | 0.019 | -0.023          | 0.936 | 0.185          | 0.508 | 0.151                     | 0.591 |
| Total Motility (%)                        | -0.406 | 0.006 | 0.300           | 0.277 | -0.130         | 0.644 | -0.339                    | 0.216 |
| Progressive (%)                           | -0.405 | 0.006 | -0.027          | 0.923 | -0.179         | 0.523 | -0.039                    | 0.891 |
| Morphology (%normal)                      | -0.426 | 0.004 | 0.126           | 0.655 | 0.435          | 0.105 | 0.063                     | 0.823 |

Spearman's nonparametric correlation coefficient was calculated for data.

in spermatozoa parameters between the normozoospermic and infertile groups [46]. Besides, Kazerooni et al. found a meaningfully negative relationship between histone transition abnormality with sperm morphology and motility [47].

In contrast, the study conducted by Dehghanpour et al. [48] found no significant correlation between sperm chromatin maturity and the parameters of men with teratospermia, as determined by the CMA3 test. Moreover, the incidence of spermatozoa with abnormal chromatin condensation showed a positive correlation with sperm concentration but did not exhibit any correlation with other semen parameters, including motility and morphology [49]. Currently, the role of abnormal DNA methylation in the occurrence of human diseases is well documented [50]. The significance of methylation status in biology lies in its capacity to control gene expression [20]. Several studies found that spermatozoa from infertile patients often show higher levels of aberrant DNA methylation at imprinted loci [51,52]. When considering *MEST* methylation, the maternally methylated *MEST* DMR must have a completely unmethylated pattern [20]. Our findings indicated that the mean percentage of methylation related to *MEST* was significantly higher in the infertile group, which comprised asthenospermia and oligoasthenoteratospermia, in comparison to the fertile group (normospermia) (Table 4). Given the novelty of the study's design, it seems that the *MEST* status in oligoasthenoteratospermia cases has not been studied anywhere else in the world. However, a recent study evaluating it in the asthenospermia group was published [53].

In the aforementioned study, authors investigated *MEST* methylation in 74 men with asthenozoospermia and 92 normozoospermia individuals recruited between November 2017 and May 2019. The result confirmed a significant difference between the mild asthenospermia and fertile samples [53].

Until now, various research regarding other types of infertile groups, especially oligozoospermia, have illustrated that abnormal methylation of imprinted genes might disrupt spermatozoa production and/or lead to male factor infertility [54–57]. *MEST*, as an imprinted gene, severally has been reported as hypermethylated in male infertility [26,52,58–60]. The sample size in these studies ranges from 10 to 175 for the case group and from 5 to 119 for the control group. Santi et al. performed meta-analysis research on the impairment of spermatozoa DNA methylation in male infertility. In this comprehensive meta-analysis, comprising twenty-four studies, it was revealed that male infertility is significantly correlated with increased *MEST* methylation [61]. Klaver & Gromoll reported a greater odds ratio of abnormal DNA methylation on the *MEST* gene in infertile patients compared the healthy men [62]. Kobayashi et al. [16] investigated 97 samples, consisting of 79 normal individuals and 18 patients with oligospermia. Similarly, Poplinski et al. [27] conducted a study using bisulfite sequencing, while Sato et al. [63] analyzed 61 cases with severe oligozoospermia, 67 cases with moderate oligozoospermia, and 209 cases with normozoospermia using the combined bisulfite PCR restriction analysis (COBRA) method. These studies collectively revealed a robust association between abnormal *MEST* gene methylation and idiopathic male infertility. The literature review could not find any study that revealed a non-significant relation between *MEST* methylation pattern and infertility. Overall, correct levels of sperm DNA methylation are critical for potential fertility.

Since imbalances in the methylation levels have been diagnosed in the case of imprinting genes like *MEST* in the spermatozoa DNA of infertile patients, the importance of DNA methylation in fertility and pregnancy requires considerable consideration [55,64]. Our results suggested a negative relationship between *MEST* methylation with spermatozoa count, sperm concentration, progressive, and normal morphology (Table 5). Our results are in accord with prior research done by Song et al. [53], Laqqan et al. [65], Santana et al. [66], and Tang et al. [28] found that abnormal DNA methylation patterns were related to the weak spermatozoa parameters in infertile patients. However, a study conducted by Louie et al. could not establish a significant relationship between *MEST* methylation across sperm concentrations [20].

The following items can be nominated as limitations of the present study, and researchers can consider these suggestions for future investigations;

- 1- Recruiting additional samples from multiple treatment centers can increase the overall sample size and, as a result, improve the ability to determine the role of effect size.
- 2- Chromomycin A3 (CMA3) is another way to detect DNA and chromatin defects in sperm more accurately and sensitively compared to Aniline Blue. Additionally, the combined use of these two staining methods can increase the accuracy of chromatin assessment and aid in identifying sperm issues.
- 3- Bisulfite sequencing of specific genes offers the advantage of providing accurate quantification of multiple CpG methylation sites in the same reaction. In contrast, the qMSP assay can be designed to target one or more CpG sites within a specific genomic region, but it can only determine the overall methylation status of the entire targeted region as a whole [62]. This makes bisulfite sequencing of specific genes a more detailed and informative method for studying epigenetic modifications in DNA.
- 4- Follow-up with the participating individuals to determine the outcomes, such as embryo quality and birth rate, is recommended.

**Table 4**  
The methylation status of the *MEST* gene DMRs in normospermia and infertile subgroups.

| Variable                    | Normozoospermic (n = 15) | 95 %CI     | Infertile (n = 30) | 95 %CI      | P. <sup>a</sup> | Normozoospermic (n = 15) | 95 %CI     | Asthenospermia (n = 15) | 95 %CI     | Oligoasthenoteratospermia (n = 15) | 95 %CI      | P. <sup>b</sup> |
|-----------------------------|--------------------------|------------|--------------------|-------------|-----------------|--------------------------|------------|-------------------------|------------|------------------------------------|-------------|-----------------|
| <i>MEST</i> methylation (%) | 10.35 ± 15.96            | 3.15–19.20 | 21.35 ± 27.99      | 11.37–31.88 | 0.045           | 10.35 ± 15.96            | 1.51–19.19 | 10.24 ± 18.0            | 0.27–20.21 | 32.47 ± 32.16                      | 14.66–50.29 | 0.014           |

<sup>a</sup> Relationships between sperm parameters in normospermia and infertile group were determined with the nonparametric Mann-Whitney *U* test.

<sup>b</sup> P-value obtained from the difference between means in normospermia, asthenospermia, and oligoasthenoteratospermia was tested for significance, by Kruskal-Wallis one way ANOVA on ranks and post hoc analysis was performed using Dunn's for all pair-wise comparisons.  $p < 0.05$  was considered statistically significant.

**Table 5**  
Correlation between sperm parameters with *MEST* methylation.

| Sperm parameters                                  | Total (N = 45) |       | Normozoospermic (N = 15) |       | Asthenospermia (N = 15) |       | Oligoasthenoteratospermia (N = 15) |       |
|---|----------------|-------|--------------------------|-------|-------------------------|-------|------------------------------------|-------|
|   | r              | P     | r                        | P     | r                       | P     | r                                  | P     |
| Sperm Count (10 <sup>6</sup> cells per ejaculate) | -0.374         | 0.011 | 0.143                    | 0.611 | -0.393                  | 0.147 | 0.089                              | 0.752 |
| Sperm Concentration (10 <sup>6</sup> cells/mL)    | -0.325         | 0.029 | 0.249                    | 0.371 | -0.118                  | 0.674 | 0.224                              | 0.422 |
| Total Motility (%)                                | -0.234         | 0.121 | -0.068                   | 0.810 | 0.343                   | 0.211 | 0.475                              | 0.073 |
| Progressive (%)                                   | -0.323         | 0.030 | 0.321                    | 0.244 | -0.140                  | 0.619 | 0.283                              | 0.307 |
| Morphology (%normal)                              | -0.384         | 0.009 | 0.174                    | 0.534 | -0.434                  | 0.106 | 0.303                              | 0.272 |
| Histone transition abnormality (%)                | 0.139          | 0.363 | 0.096                    | 0.734 | -0.077                  | 0.784 | -0.282                             | 0.309 |

Spearman's nonparametric correlation coefficient was calculated for data.

## 5. Conclusion

A negative correlation existed between the histone transition abnormality and *MEST* methylation with sperm parameters. In addition, chromatin integrity, sperm maturity, and *MEST* methylation may be considered important predictors for the assessment of male fertility potential.

## Author contribution statement

Tayebeh Amjadian: Conceived and designed the experiments; Performed the experiments; Wrote the paper.

Parichehreh Yaghmaei: Analyzed and interpreted the data; Wrote the paper.

Nasim Hayati Roodbari: Contributed reagents, materials, analysis tools or data; Wrote the paper.

Kheirollah Yari: Conceived and designed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

## Funding statement

This study was not funded by anywhere/anyone.

## Data availability statement

Data will be made available on request.

## Ethics statement

The Research Ethics Committee at the Deputy of Research of Islamic Azad University approved the study protocol (IR.IAU.SRB.REC.1401.184). All participants were required to sign a written consent form and were provided with a participant information statement that thoroughly explained the consent process.

## Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgment

The authors would like to thank the ACECR, Infertility Treatment Center, Kermanshah, Iran for the support, cooperation, and assistance throughout the study. Also, we thank our willing and helpful participants.

## References

- [1] E. Kazemi, J. Zargooshi, M. Kaboudi, F. Izadi, H.-R.M. Motlagh, D. Kahrizi, et al., Investigation of gene expression and genetic simultaneous control associated with erectile dysfunction and diabetes, *Cell. Mol. Biol.* 67 (2021) 195–200.
- [2] E. Kazemi, J. Zargooshi, M.F. Dehpahni, H.-R.M. Motlagh, M. Kaboudi, D. Kahrizi, et al., Androgen regulated protein and pyruvate dehydrogenase kinase 4 in severe erectile dysfunction: a gene expression analysis, and computational study of protein structure, *Cell. Mol. Biol.* 67 (2021) 89–94.
- [3] F.N.K. Sabir, Association of Anti-Mullerian Hormone with some physiological and immunological parameters of infertile males, *Cell. Mol. Biol.* 68 (2022) 171–178.
- [4] W. Cui, *Mother or Nothing: the Agony of Infertility*, vol. 88, World Health Organization Bulletin of the World Health Organization, 2010, p. 881.
- [5] H. Cao, L. Wang, H. Wu, Relationship between the characteristics of vaginal secretion, reproductive immune antibody and infertility, *Cell. Mol. Biol.* 68 (2022) 126–131.
- [6] A. Agarwal, A. Mulgund, A. Hamada, M.R. Chyatte, A unique view on male infertility around the globe, *Reprod. Biol. Endocrinol.* 13 (2015) 1–9.



- [7] E.T. Marzouni, H. Ilkhani, A.B. Harchegani, H. Shafaghathian, I. Layali, A. Shahriary, Epigenetic modifications, A new approach to male infertility etiology: a review, *Int. J. Fertil. Steril.* 16 (2022) 1.
- [8] M.I. Cedars, In vitro fertilization and risk of autistic disorder and mental retardation, *JAMA* 310 (2013) 42–43.
- [9] J. Huntriss, H.M. Picton, Epigenetic consequences of assisted reproduction and infertility on the human preimplantation embryo, *Hum. Fertil.* 11 (2008) 85–94.
- [10] S.K. Zaidi, D.W. Young, M. Montecino, J.B. Lian, J.L. Stein, A.J. Van Wijnen, et al., Architectural epigenetics: mitotic retention of mammalian transcriptional regulatory information, *Mol. Cell Biol.* 30 (2010) 4758–4766.
- [11] C.P. Riedstra, C. Tzagarakis-Foster, Investigation of epigenetic control of DAX-1 expression in human cell lines, *J. Endocr.Soc.* 5 (2021) A506–A507.
- [12] M. Ma, W. Wang, B. Wang, Y. Yang, Y. Huang, G. Zhao, et al., The prognostic value of N6-methyladenosine RBM15 regulators in lung adenocarcinoma, *Cell. Mol. Biol.* 68 (2022) 130–139.
- [13] Y. Zhang, N. Lu, S. Pu, K. Mu, Significance of screening sensitive methylation sites using whole-genome sequencing in early diagnosis of non-small cell lung cancer, *Cell. Mol. Biol.* 67 (2021) 218–226.
- [14] A. Uk, S. Collardeau-Frachon, Q. Scavion, L. Michon, E. Amar, Assisted Reproductive Technologies and imprinting disorders: results of a study from a French congenital malformations registry, *Eur. J. Med. Genet.* 61 (2018) 518–523.
- [15] E.L. Niemitz, A.P. Feinberg, Epigenetics and assisted reproductive technology: a call for investigation, *Am. J. Hum. Genet.* 74 (2004) 599–609.
- [16] H. Kobayashi, A. Sato, E. Otsu, H. Hiura, C. Tomatsu, T. Utsunomiya, et al., Aberrant DNA methylation of imprinted loci in sperm from oligospermic patients, *Hum. Mol. Genet.* 16 (2007) 2542–2551.
- [17] C. Marques, P. Costa, B. Vaz, F. Carvalho, S. Fernandes, A. Barros, et al., Abnormal methylation of imprinted genes in human sperm is associated with oligozoospermia, *Mol. Hum. Reprod.* 14 (2008) 67–74.
- [18] W. He, Y. Sun, S. Zhang, X. Feng, M. Xu, J. Dai, et al., Profiling the DNA methylation patterns of imprinted genes in abnormal semen samples by next-generation bisulfite sequencing, *J. Assist. Reprod. Genet.* 37 (2020) 2211–2221.
- [19] A.M. Riesewijk, L. Hu, U. Schulz, G. Tariverdian, P. Höglund, J. Kere, et al., Monoallelic expression of human PEG1/MESTs paralleled by parent-specific methylation in fetuses, *Genomics* 42 (1997) 236–244.
- [20] K. Louie, A. Minor, R. Ng, K. Poon, V. Chow, S. Ma, Evaluation of DNA methylation at imprinted DMRs in the spermatozoa of oligozoospermic men in association with MTHFR C677T genotype, *Andrology* 4 (2016) 825–831.
- [21] N. Schöherr, S. Jäger, M.B. Ranke, H.A. Wollmann, G. Binder, T. Eggermann, No evidence for isolated imprinting mutations in the PEG1/MEST locus in Silver–Russell patients, *Eur. J. Med. Genet.* 51 (2008) 322–324.
- [22] Y.-S. Moon, S.-K. Park, H.-T. Kim, T.S. Lee, J.H. Kim, Y.S. Choi, Imprinting and expression status of isoforms 1 and 2 of PEG1/MEST gene in uterine leiomyoma, *Gynecol. Obstet. Invest.* 70 (2010) 120–125.
- [23] H. Nakanishi, T. Suda, M. Katoh, A. Watanabe, T. Igishi, M. Kodani, et al., Loss of imprinting of PEG1/MEST in lung cancer cell lines, *Oncol. Rep.* 12 (2004) 1273–1278.
- [24] W. Shi, L. Lefebvre, Y. Yu, S. Otto, A. Krella, A. Orth, et al., Loss-of-imprinting of Peg1 in mouse interspecies hybrids is correlated with altered growth, *Genesis* 39 (2004) 65–72.
- [25] S. Katari, N. Turan, M. Bibikova, O. Erinle, R. Chalian, M. Foster, et al., DNA methylation and gene expression differences in children conceived in vitro or in vivo, *Hum. Mol. Genet.* 18 (2009) 3769–3778.
- [26] S.S. Hammoud, J. Purwar, C. Pflueger, B.R. Cairns, D.T. Carrell, Alterations in sperm DNA methylation patterns at imprinted loci in two classes of infertility, *Fertil. Steril.* 94 (2010) 1728–1733.
- [27] A. Poplinski, F. Tüttelmann, D. Kanber, B. Horsthemke, J. Gromoll, Idiopathic male infertility is strongly associated with aberrant methylation of MEST and IGF2/H19 ICR1, *Int. J. Androl.* 33 (2010) 642–649.
- [28] Q. Tang, F. Pan, J. Yang, Z. Fu, Y. Lu, X. Wu, et al., Idiopathic male infertility is strongly associated with aberrant DNA methylation of imprinted loci in sperm: a case-control study, *Clin. epigenetics.* 10 (2018) 1–10.
- [29] D. Montjean, A. Zini, C. Ravel, S. Belloc, A. Dalleac, H. Copin, et al., Sperm global DNA methylation level: association with semen parameters and genome integrity, *Andrology* 3 (2015) 235–240.
- [30] T. Irez, N. Dayioglu, M. Alagöz, S. Karatas, O. Güralp, The use of aniline blue chromatin condensation test on prediction of pregnancy in mild male factor and unexplained male infertility, *Andrologia* 50 (2018), e13111.
- [31] S. Dutta, R. Henkel, A. Agarwal, Comparative analysis of tests used to assess sperm chromatin integrity and DNA fragmentation, *Andrologia* 53 (2021), e13718.
- [32] R. Oliva, Protamines and male infertility, *Hum. Reprod. Update* 12 (2006) 417–435.
- [33] D. Quejck, Evaluation of protamine level in human sperm samples using chromomycin a3 and aniline blue staining, *Res. Mol. Med.* 4 (2016) 50–55.
- [34] F.E. Duncan, E. Feinberg, R.E. Brannigan, M. Edmonds, L. Ataman, T.K. Woodruff, Chapter 33 - fertility preservation, in: J.F. Strauss, R.L. Barbieri (Eds.), *Yen and Jaffe's Reproductive Endocrinology*, eighth ed., Elsevier, Philadelphia, 2019, 857–86.e6.
- [35] A. Agarwal, R. Sharma, S. Gupta, R. Finelli, N. Parekh, M.K.P. Selvam, et al., Standardized laboratory procedures, quality control and quality assurance are key requirements for accurate semen analysis in the evaluation of infertile male, *World J. Mens. Health.* 40 (2022) 52–65.
- [36] W.H. Organization, WHO Laboratory Manual for the Examination and Processing of Human Semen, World Health Organization, 2021.
- [37] M. Abdulla, M. Ahmed, A. Barakat, Comparison of swim down and density gradient sperm preparation methods in terms of motility, morphology and DNA fragmentation, *Am. J. Life Sci. Res.* 3 (2015).
- [38] D. Franken, C. Franken, H. De La Guere, A. De Villiers, Normal sperm morphology and chromatin packaging: comparison between aniline blue and chromomycin A3 staining, *Andrologia* 31 (1999) 361–366.
- [39] K. Yari, Z. Rahimi, Promoter methylation status of the retinoic acid receptor-beta 2 gene in breast cancer patients: a case control study and systematic review, *Breast Care* 14 (2019) 117–123.
- [40] K. Yari, M. Payandeh, Z.J.T.B. Rahimi, Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran, *Tumor Biol.* 37 (2016) 8145–8152.
- [41] S. Pourmasumi, A. Khoradmehr, T. Rahiminia, P. Sabeti, A.R. Talebi, J. Ghasemzadeh, Evaluation of sperm chromatin integrity using aniline blue and toluidine blue staining in infertile and normozoospermic men, *J. Reprod. Infertil.* 20 (2019) 95.
- [42] E.M. Ameen, F.N.K. Sabir, S.I. Mohammed, Relationships between semen quality and fertility in a population of infertile men in Erbil city, *Cell. Mol. Biol.* 68 (2022) 63–68.
- [43] A.A. Al-Fahham, Y.K. Al-Sultani, A.K. Muhammad-Ali, Using sperm chromatin staining techniques as a predictive diagnostic tool for male infertility, *Kufa J. Nurs. Sci.* 4 (2014).
- [44] H.-S. Kim, M.J. Kang, S.A. Kim, S.K. Oh, H. Kim, S.-Y. Ku, et al., The utility of sperm DNA damage assay using toluidine blue and aniline blue staining in routine semen analysis, *Clin. Exp. Reprod. Med.* 40 (2013) 23.
- [45] A. Sellami, N. Chakroun, S. Ben Zarrouk, H. Sellami, S. Kebaili, T. Rebai, et al., Assessment of chromatin maturity in human spermatozoa: useful aniline blue assay for routine diagnosis of male infertility, *Adv. Urol.* 2013 (2013).
- [46] M. Hammadeh, T. Zeginiadov, P. Rosenbaum, T. Georg, W. Schmidt, E. Strehler, Predictive value of sperm chromatin condensation (aniline blue staining) in the assessment of male fertility, *Arch. Androl.* 46 (2001) 99–104.
- [47] T. Kazerooni, N. Asadi, L. Jadid, M. Kazerooni, A. Ghanadi, F. Ghaffarpassand, et al., Evaluation of sperm's chromatin quality with acridine orange test, chromomycin A3 and aniline blue staining in couples with unexplained recurrent abortion, *J. Assist. Reprod. Genet.* 26 (2009) 591–596.
- [48] F. Dehghanpour, F. Fesahat, F. Yazdinejad, L. Motamedzadeh, A.R. Talebi, Is there any relationship between human sperm parameters and protamine deficiency in different groups of infertile men? *Rev. Int. Androl.* 18 (2020) 137–143.
- [49] S. Karydis, B. Asimakopoulou, N. Papadopoulos, I. Vakalopoulos, S. Al-Hasani, N. Nikolettos, ICSI outcome is not associated with the incidence of spermatozoa with abnormal chromatin condensation, *In vivo* 19 (2005) 921–925.
- [50] D. Filippini, R. Feil, Perturbation of genomic imprinting in oligozoospermia, *Epigenetics* 4 (2009) 27–30.

- [51] S. Houshdaran, V.K. Cortessis, K. Siegmund, A. Yang, P.W. Laird, R.Z. Sokol, Widespread epigenetic abnormalities suggest a broad DNA methylation erasure defect in abnormal human sperm, *PLoS One* 2 (2007) e1289.
- [52] C.J. Marques, F. Carvalho, M. Sousa, A. Barros, Genomic imprinting in disruptive spermatogenesis, *The Lancet* 363 (2004) 1700–1702.
- [53] B. Song, Y. Chen, C. Wang, G. Li, Z. Wei, X. He, et al., Poor semen parameters are associated with abnormal methylation of imprinted genes in sperm DNA, *Reprod. Biol. Endocrinol.* 20 (2022) 1–7.
- [54] E. Pohl, J. Gromoll, J. Wistuba, S. Laurentino, Healthy ageing and spermatogenesis, *Reproduction* 161 (2021) R89–R101.
- [55] F. Åsenius, A.F. Danson, S.J. Marzi, DNA methylation in human sperm: a systematic review, *Hum. Reprod. Update* 26 (2020) 841–873.
- [56] S. Laurentino, L. Heckmann, S. Di Persio, X. Li, G. Meyer zu Hörste, J. Wistuba, et al., High-resolution analysis of germ cells from men with sex chromosomal aneuploidies reveals normal transcriptome but impaired imprinting, *Clin. Epigenetics*. 11 (2019) 1–13.
- [57] L. Das, S. Parbin, N. Pradhan, C. Kausar, S.K. Patra, Epigenetics of reproductive infertility, *Front. Biosci.* 9 (2017) 509–535.
- [58] J. Xu, A. Zhang, Z. Zhang, P. Wang, Y. Qian, L. He, et al., DNA methylation levels of imprinted and nonimprinted genes DMR s associated with defective human spermatozoa, *Andrologia* 48 (2016) 1027–1035.
- [59] D. Montjean, C. Ravel, M. Benkhalifa, P. Cohen-Bacrie, I. Berthaut, A. Bashamboo, et al., Methylation changes in mature sperm deoxyribonucleic acid from oligozoospermic men: assessment of genetic variants and assisted reproductive technology outcome, *Fertil. Steril.* 100 (2013) 1241–1247, e2.
- [60] N. El Hajj, U. Zechner, E. Schneider, A. Tresch, J. Gromoll, T. Hahn, et al., Methylation status of imprinted genes and repetitive elements in sperm DNA from infertile males, *Sex. Dev.* 5 (2011) 60–69.
- [61] D. Santi, S. De Vincentis, E. Magnani, G. Spaggiari, Impairment of sperm DNA methylation in male infertility: a meta-analytic study, *Andrology* 5 (2017) 695–703.
- [62] R. Kläver, J. Gromoll, Bringing epigenetics into the diagnostics of the andrology laboratory: challenges and perspectives, *Asian J. Androl.* 16 (2014) 669.
- [63] A. Sato, H. Hiura, H. Okae, N. Miyauchi, Y. Abe, T. Utsunomiya, et al., Assessing loss of imprint methylation in sperm from subfertile men using novel methylation polymerase chain reaction Luminex analysis, *Fertil. Steril.* 95 (2011), 129–34. e4.
- [64] J.C. Rotondo, C. Lanzillotti, C. Mazziotta, M. Tognon, F. Martini, Epigenetics of male infertility: the role of DNA methylation, *Front. Cell Dev. Biol.* (2021) 1822.
- [65] M. Laqqan, M. Hammadeh, Aberrations in sperm DNA methylation patterns of males suffering from reduced fecundity, *Andrologia* 50 (2018), e12913.
- [66] V.P. Santana, E.R. James, C.L. Miranda-Furtado, M.F. de Souza, C.P. Pompeu, S.C. Esteves, et al., Differential DNA methylation pattern and sperm quality in men with varicocele, *Fertil. Steril.* 114 (2020) 770–778.
- [67] K. Kosaki, R. Kosaki, W.P. Robinson, W.J. Craigen, L.G. Shaffer, S. Sato, et al., Diagnosis of maternal uniparental disomy of chromosome 7 with a methylation specific PCR assay, *J. Med. Genet.* 37 (2000) e19–e.